Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 4/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16145028 | 0.87 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL6682201 | 0.84 | MAPK1 (0.64) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL8359453 | 0.84 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL14353222 | 0.81 | MAOA (0.59) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL3991531 | 0.81 | MAOA (0.59) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| Digiferruginol SCHEMBL23199057 | 0.81 | ELANE (0.69) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| Digiferruginol SCHEMBL30614617 | 0.81 | ELANE (0.69) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL2398142 | 0.79 | ELANE (0.50) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL2396651 | 0.79 | ELANE (0.53) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL2396782 | 0.79 | ELANE (0.50) | MEN1KMT2AALDH1A1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170307-A2 | INHIBITION OF AGE FORMATION | BASF Beauty Care Solutions France SAS (FR) | 2010-04-07 | — | — | EP | claimed |
| CN-101686954-A | The inhibition that AGE forms | BASF BEAUTY CARE SOLUTIONS F | 2010-03-31 | — | — | CN | claimed |
| WO-2009007411-A2 | INHIBITION OF AGE FORMATION | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2009-01-15 | — | — | WO | claimed |
| CN-115025129-B | Composition containing lactobacillus and use thereof for preventing and/or improving skin aging | 葡萄王生技股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3342396-B1 | EXTERNAL PREPARATION FOR SKIN FOR REDUCING SKIN YELLOWNESS | HAYASHIBARA CO (JP) | 2023-04-12 | — | — | EP | disclosed |
| CN-115025129-A | Lactobacillus-containing composition and application thereof in preventing and/or improving skin aging | 葡萄王生技股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-107920981-B | Skin external preparation for reducing dark yellow | 株式会社林原 | 2021-06-08 | — | — | CN | disclosed |
| EP-3398585-B1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | HAYASHIBARA CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-10568827-B2 | External dermal agent for reducing yellowish dullness | Hayashibara Co., Ltd. (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20190008747-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2019-01-10 | — | — | US | disclosed |
| CN-105585601-B | Anti-aging skin external composition and preparation method thereof | 株式会社林原 | 2018-11-13 | — | — | CN | disclosed |
| US-20130078202-A1 | INHIBITION OF THE FORMATION OF AGEs | BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) | 2013-03-28 | — | — | US | disclosed |
| US-20100316743-A1 | INHIBITION OF THE FORMATION OF AGEs | BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20100203175-A1 | DEGLYCATION OF AGEs | BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) | 2010-08-12 | — | — | US | disclosed |
| CN-101765432-A | AGE deglycation | BASF BEAUTY CARE SOLUTIONS F | 2010-06-30 | — | — | CN | disclosed |
| EP-2170358-A2 | AGE DEGLYCATION. | BASF Beauty Care Solutions France SAS (FR) | 2010-04-07 | — | — | EP | disclosed |
| EP-2170307-A2 | INHIBITION OF AGE FORMATION | BASF Beauty Care Solutions France SAS (FR) | 2010-04-07 | — | — | EP | disclosed |
| CN-101686954-A | The inhibition that AGE forms | BASF BEAUTY CARE SOLUTIONS F | 2010-03-31 | — | — | CN | disclosed |
| WO-2009007411-A2 | INHIBITION OF AGE FORMATION | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007412-A2 | AGE DEGLYCATION | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316743-A1 | INHIBITION OF THE FORMATION OF AGEs | AGER, GLA, S100A6 | MEN1 2572/4885KMT2A 3739/4885ALDH1A1 1259/4885 |
| US-20130078202-A1 | INHIBITION OF THE FORMATION OF AGEs | AGER, GLA, S100A6 | MEN1 2572/4885KMT2A 3739/4885ALDH1A1 1259/4885 |
| US-10568827-B2 | External dermal agent for reducing yellowish dullness | FUT5, ENGASE, FUT6 | MEN1 4298/4885KMT2A 1445/4885ALDH1A1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.